Proteomics and cancer epidemiology

Methods in Molecular Biology

Volumn 471, Issue , 2009, Pages 197-215

  Verma, Mukesh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

2 dimensional polyacrylamide gel electrophoresis (2D PAGE); Artificial intelligence; Biomarker; Chromatin; Epigenetics; Histone; Matrix assisted laser desorption ionization (MALDI) mass spectrometry; Methylation; Proteomics; Risk assessment

Indexed keywords

ARTIFICIAL INTELLIGENCE; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ARTIFICIAL INTELLIGENCE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NEOPLASMS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 60349085699     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-416-2_10     Document Type: Review

References (102)

1. Hanash, S. (2004) HUPO initiatives relevant to clinical proteomics. Mol Cell Proteomics 3, 298-301.
2. Omenn, G. S., States, D. J., Adamski, M., Blackwell, T. W., Menon, R., Hermjakob, H., Apweiler, R., Haab, B. B., Simpson, R. J., Eddes, J. S., Kapp, E. A., Moritz, R. L., Chan, D. W., Rai, A. J., Admon, A., Aebersold, R., Eng, J., Hancock, W. S., Hefta, S. A., Meyer, H., Paik, Y. K., Yoo, J. S., Ping, P., Pounds, J., Adkins, J., Qian, X., Wang, R., Wasinger, V., Wu, C. Y., Zhao, X., Zeng, R., Archakov, A., Tsugita, A., Beer, I., Pandey, A., Pisano, M., Andrews, P., Tammen, H., Speicher, D. W., and Hanash, S. M. (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5, 3226-3245.
3. States, D. J., Omenn, G. S., Blackwell, T. W., Fermin, D., Eng, J., Speicher, D. W., and Hanash, S. M. (2006) Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 24, 333-338.
4. Imafuku, Y., Omenn, G. S., and Hanash, S. (2004) Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20, 149-153.
5. Misek, D. E., Imafuku, Y., and Hanash, S. M. (2004) Application of proteomic technologies to tumor analysis. Pharmacogenomics 5, 1129-1137.
6. Misek, D. E., Kuick, R., Wang, H., Galchev, V., Deng, B., Zhao, R., Tra, J., Pisano, M. R., Amunugama, R., Allen, D., Walker, A. K., Strahler, J. R., Andrews, P., Omenn, G. S., and Hanash, S. M. (2005) A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 5, 3343-3352.
7. Song, K., and Hanash, S. (2006) Unraveling the complex proteome for biomarker discovery in gastrointestinal and liver diseases. Gastroenterology 131, 1375-1378.
8. Steel, L. F., Haab, B. B., and Hanash, S. M. (2005) Methods of comparative proteomic profiling for disease diagnostics. J Chromatogr 815, 275-284.
9. Xia, W. Y., Lien, H. C., Wang, S. C., Pan, Y., Sahin, A., Kuo, Y. H., Chang, K. J., Zhou, X., Wang, H., Yu, Z., Hortobagyi, G., Shi, D. R., and Hung, M. C. (2006) Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98, 295-301.
10. Li, M., Song, T., Yin, Z. F., and Na, Y. Q. (2007) XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Chin Med J 120, 469-473.
11. Shioi, K., Komiya, A., Hattori, K., Huang, Y., Sano, F., Murakami, T., Nakaigawa, N., Kishida, T., Kubota, Y., Nagashima, Y., and Yao, M. (2006) Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res 12, 7339-7346.
12. Selvarajan, S., Wong, K. Y., Khoo, K. S., Bay, B. H., and Tan, P. H. (2006) Over-expression of c-erbB-2 correlates with nuclear morphometry and prognosis in breast carcinoma in Asian women. Pathology 38, 528-533.
13. Short, S. M., Yoder, B. J., Tarr, S. M., Prescott, N. L., Laniauskas, S., Coleman, K. A., Downs-Kelly, E., Pettay, J. D., Choueiri, T. K., Crowe, J. P., Tubbs, R. R., Budd, T. G., and Hicks, D. G. (2007) The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J 13, 130-139.
14. Gosens, M. J., van Kempen, L. C., van de Velde, C. J., van Krieken, J. H., and Nagtegaal, I. D. (2007) Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 20, 221-232.
15. Heinzerling, J. H., Anthony, T., Livingston, E. H., and Huerta, S. (2007) Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am Surg 73, 230-238.
16. Natsugoe, S., Uchikado, Y., Okumura, H., Matsumoto, M., Setoyama, T., Tamotsu, K., Kita, Y., Sakamoto, A., Owaki, T., Ishigami, S., and Aikou, T. (2007) Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep 17, 517-523.
17. Sugiura, K., Ozawa, S., Kitagawa, Y., Ueda, M., and Kitajima, M. (2007) Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 17, 557-564.
18. de Mingo, M., Moran, A., Sanchez-Pernaute, A., Iniesta, P., Diez-Valladares, L., Perez-Aguirre, E., de Juan, C., Garcia-Aranda, C., Diaz-Lopez, A., Garcia-Botella, A., Martin-Antona, E., Benito, M., Torres, A., and Balibrea, J. L. (2007) Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepato-gastroenterology 54, 315-319.
19. Smilek, P., Dusek, L., Vesely, K., Rottenberg, J., and Kostrica, R. (2006) Correlation of expression of Ki-67, EGFR, c-erbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer. J Exp Clin Cancer Res 25, 549-555.
20. Ohshiro, K., Rosenthal, D. I., Koomen, J. M., Streckfus, C. F., Chambers, M., Kobayashi, R., and El-Naggar, A. K. (2007) Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma. Int J Oncol 30, 743-749.
21. Zhong, L., Coe, S. P., Stromberg, A. J., Khattar, N. H., Jett, J. R., and Hirschowitz, E. A. (2006) Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1, 513-519.
22. Materna, V., Surowiak, P., Markwitz, E., Spaczynski, M., Drag-Zalesinska, M., Zabel, M., and Lage, H. (2007) Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep 17, 505-516.
23. Fall, K., Garmo, H., Andren, O., Bill-Axelson, A., Adolfsson, J., Adami, H. O., Johansson, J. E., and Holmberg, L. (2007) Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99, 526-532.
24. Garcia, J. A., Rosenberg, J. E., Weinberg, V., Scott, J., Frohlich, M., Park, J. W., and Small, E. J. (2007) Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int 99, 519-524.
25. Gondi, V., Deutsch, I., Mansukhani, M., O'Toole, K. M., Shah, J. N., Schiff, P. B., Katz, A. E., Benson, M. C., Goluboff, E. T., and Ennis, R. D. (2007) Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. Urology 69, 541-546.
26. McFall, S. L. (2007) Use and awareness of prostate specific antigen tests and race/ethnicity. J Urol 177 , 1475-1480; discussion 1480.
27. Parekh, D. J., Ankerst, D. P., and Thompson, I. M. (2007) Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. J Natl Cancer Inst 99, 496-497.
28. Pelzer, A. E., Bektic, J., Akkad, T., Ongarello, S., Schaefer, G., Schwentner, C., Frauscher, F., Bartsch, G., and Horninger, W. (2007) Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. J Urol 178, 93-97; discussion 97.
29. Mallikarjuna, K., Pushparaj, V., Biswas, J., and Krishnakumar, S. (2007) Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 32, 281-290.
30. Barry, W. T., Nobel, A. B., and Wright, F. A. (2005) Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics (Oxford, England) 21, 1943-1949.
31. Czibere, A., Grall, F., and Aivado, M. (2006) Perspectives of proteomics in acute myeloid leukemia. Expert Rev Anticancer Ther 6, 1663-1675.
32. Diamandis, E. P. (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96, 353-356.
33. Fields, M. M., and Chevlen, E. (2006) Ovarian cancer screening: a look at the evidence. Clin J Oncol Nurs 10, 77-81.
34. Gharib, T. G., Chen, G., Wang, H., Huang, C. C., Prescott, M. S., Shedden, K., Misek, D. E., Thomas, D. G., Giordano, T. J., Taylor, J. M., Kardia, S., Yee, J., Orringer, M. B., Hanash, S., and Beer, D. G. (2002) Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 4, 440-448.
35. Kolch, W., Mischak, H., and Pitt, A. R. (2005) The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 108, 369-383.
36. Kumar, S., Mohan, A., and Guleria, R. (2006) Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11, 385-405.
37. Lewis, S., and Menon, U. (2003) Screening for ovarian cancer. Expert Rev Anticancer Ther 3, 55-62.
38. Preston, R. J. (2002) Quantitation of molecular endpoints for the dose-response component of cancer risk assessment. Toxicol Pathol 30, 112-116.
39. Pusztai, L., Gregory, B. W., Baggerly, K. A., Peng, B., Koomen, J., Kuerer, H. M., Esteva, F. J., Symmans, W. F., Wagner, P., Hortobagyi, G. N., Laronga, C., Semmes, O. J., Wright, G. L., Jr., Drake, R. R., and Vlahou, A. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100, 1814-1822.
40. Ricolleau, G., Charbonnel, C., Lode, L., Loussouarn, D., Joalland, M. P., Bogumil, R., Jourdain, S., Minvielle, S., Campone, M., Deporte-Fety, R., Campion, L., and Jezequel, P. (2006) Surface-enhanced laser desorption/ ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6, 1963-1975.
41. Scagliotti, G. V., and Novello, S. (2004) Current development of adjuvant treatment of non-small-cell lung cancer. Clin Lung Cancer 6(Suppl 2), S63-70.
42. Seibert, V., Ebert, M. P., and Buschmann, T. (2005) Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomics Proteomics 4, 16-26.
43. Verma, M. (2004) Biomarkers for risk assessment in molecular epidemiology of cancer. Technol Cancer Res Treat 3, 505-514.
44. Al-Abbadi, M. A., Hattab, E. M., Tarawneh, M., Orazi, A., and Ulbright, T. M. (2007) Primary testicular and paratesticular lymphoma: a retrospective clinicopathologic study of 34 cases with emphasis on dif ferential diagnosis. Archives of pathology & laboratory medicine 131, 1040-1046.
45. Puhalla, H., Wrba, F., Kandioler, D., Lehnert, M., Huynh, A., Gruenberger, T., Tamandl, D., and Filipits, M. (2007) Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/ neu in patients with gallbladder cancer. Anticancer Res 27, 1679-1684.
46. Spanjol, J., Maricic, A., Cicvaric, T., Valencic, M., Oguic, R., Tadin, T., Fuckar, D., and Bobinac, M. (2007) Epidemiology of prostate cancer in the mediterranean population of Croatia-a thirty-three year retrospective study. Coll Antropol 31, 235-239.
47. Athanassiadou, P., Athanassiades, P., Grapsa, D., Gonidi, M., Athanassiadou, A. M., Stamati, P. N., and Patsouris, E. (2007) The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer 17, 697-704.
48. Kwon, K. Y., Ro, J. Y., Singhal, N., Killen, D. E., Sienko, A., Allen, T. C., Zander, D. S., Barrios, R., Haque, A., and Cagle, P. T. (2007) MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med 131, 593-598.
49. Verma, M. (2005) Pancreatic cancer epidemiology. Technol Cancer Res Treat 4, 295-301.
50. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., and Li, D. (2004) Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64, 9018-9026.
51. Rosenfeld, J., Capdevielle, J., Guillemot, J. C., and Ferrara, P. (1992) In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem 203 , 173-179.
52. Person, M. D., Lo, H. H., Towndrow, K. M., Jia, Z., Monks, T. J., and Lau, S. S. (2003) Comparative identification of prostanoid inducible proteins by LC-ESI-MS/ MS and MALDI-TOF mass spectrometry. Chem Res Toxicology 16, 757-767.
53. Jia, Z., Person, M. D., Dong, J., Shen, J., Hensley, S. C., Stevens, J. L., Monks, T. J., and Lau, S. S. (2004) Grp78 is essential for 11-deoxy-16,16-dimethyl PGE2-mediated cytoprotection in renal epithelial cells. Am J Physiol 287, F1113-1122.
54. Clauser, K. R., Baker, P., and Burlingame, A. L. (1999) Role of accurate mass measurement (+/-10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem 71, 2871-2882.
55. Negm, R. S., Verma, M., and Srivastava, S. (2002) The promise of biomarkers in cancer screening and detection. Trends Mol Med 8, 288-293.
56. Srinivas, P. R., Verma, M., Zhao, Y., and Srivastava, S. (2002) Proteomics for cancer biomarker discovery. Clin Chem 48 , 1160-1169.
57. Verma, M., Kagan, J., Sidransky, D., and Srivastava, S. (2003) Proteomic analysis of cancer-cell mitochondria. Nat Rev 3, 789-795.
58. Verma, M., and Srivastava, S. (2003) New cancer biomarkers deriving from NCI early detection research. Rec Res Cancer Res 163, 72-84; discussion 264-266.
59. Verma, M., Wright, G. L., Jr., Hanash, S. M., Gopal-Srivastava, R., and Srivastava, S. (2001) Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci 945, 103-115.
60. Wagner, P. D., Verma, M., and Srivastava, S. (2004) Challenges for biomarkers in cancer detection. Ann N Y Acad Sci 1022, 9-16.
61. Wilson, L. L., Tran, L., Morton, D. L., and Hoon, D. S. (2004) Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann N Y Acad Sci 1022, 317-322.
62. Espina, V., Wulfkuhle, J. D., Calvert, V. S., VanMeter, A., Zhou, W., Coukos, G., Geho, D. H., Petricoin, E. F., 3rd, and Liotta, L. A. (2006) Laser-capture microdissection. Nat Protoc 1, 586-603.
63. Gillespie, J. W., Gannot, G., Tangrea, M. A., Ahram, M., Best, C. J., Bichsel, V. E., Petricoin, E. F., Emmert-Buck, M. R., and Chuaqui, R. F. (2004) Molecular profiling of cancer. Toxicol Pathol 32(Suppl 1), 67-71.
64. Gulmann, C., Sheehan, K. M., Kay, E. W., Liotta, L. A., and Petricoin, E. F., 3rd (2006) Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 208, 595-606.
65. Liotta, L. A., and Petricoin, E. F., 3rd (2003) The promise of proteomics. Clin Adv Hematol Oncol 1, 460-462.
66. Petricoin, E. F., Belluco, C., Araujo, R. P., and Liotta, L. A. (2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6, 961-967.
67. Stone, J. H., Rajapakse, V. N., Hoffman, G. S., Specks, U., Merkel, P. A., Spiera, R. F., Davis, J. C., St Clair, E. W., McCune, J., Ross, S., Hitt, B. A., Veenstra, T. D., Conrads, T. P., Liotta, L. A., and Petricoin, E. F., 3rd (2005) A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum 52, 902-910.
68. Wulfkuhle, J. D., Edmiston, K. H., Liotta, L. A., and Petricoin, E. F., 3rd (2006) Technology insight: pharmacoproteomics for cancer - promises of patient-tailored medicine using protein microarrays. Nat Clin Pract 3, 256-268.
69. Liggett, W. S., Barker, P. E., Semmes, O. J., and Cazares, L. H. (2004) Measurement reproducibility in the early stages of biomarker development. Dis Markers 20 , 295-307.
70. Schwegler, E. E., Cazares, L., Steel, L. F., Adam, B. L., Johnson, D. A., Semmes, O. J., Block, T. M., Marrero, J. A., and Drake, R. R. (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (Baltimore) 41, 634-642.
71. Semmes, O. J., Feng, Z., Adam, B. L., Banez, L. L., Bigbee, W. L., Campos, D., Cazares, L. H., Chan, D. W., Grizzle, W. E., Izbicka, E., Kagan, J., Malik, G., McLerran, D., Moul, J. W., Partin, A., Prasanna, P., Rosenzweig, J., Sokoll, L. J., Srivastava, S., Srivastava, S., Thompson, I., Welsh, M. J., White, N., Winget, M., Yasui, Y., Zhang, Z., and Zhu, L. (2005) Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 51, 102-112.
72. Kohli, M., Siegel, E., Bhattacharya, S., Khan, M. A., Shah, R., and Suva, L. J. (2006) Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark 2, 249-258.
73. Barbarini, N., Magni, P., and Bellazzi, R. (2006) A new approach for the analysis of mass spectrometry data for biomarker discovery. AMIA Annu Symp Proc/AMIA Symp , 26-30.
74. Kong, F., Nicole White, C., Xiao, X., Feng, Y., Xu, C., He, D., Zhang, Z., and Yu, Y. (2006) Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol 100, 247-253.
75. Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., and Farias-Eisner, R. (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5, 4589-4596.
76. Lin, Y. W., Lin, C. Y., Lai, H. C., Chiou, J. Y., Chang, C. C., Yu, M. H., and Chu, T. Y. (2006) Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 16(Suppl 1), 139-146.
77. Oh, J. H., Gao, J., Nandi, A., Gurnani, P., Knowles, L., and Schorge, J. (2005) Diagnosis of early relapse in ovarian cancer using serum proteomic profiling. Genome Inform 16, 195-204.
78. Oh, J. H., Nandi, A., Gurnani, P., Knowles, L., Schorge, J., Rosenblatt, K. P., and Gao, J. X. (2006) Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. J Bioinform Comput Biol 4, 1159-1179.
79. Wu, S. P., Lin, Y. W., Lai, H. C., Chu, T. Y., Kuo, Y. L., and Liu, H. S. (2006) SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwan J Obstet Gynecol 45, 26-32.
80. Yu, J. S., Ongarello, S., Fiedler, R., Chen, X. W., Toffolo, G., Cobelli, C., and Trajanoski, Z. (2005) Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data. Bioinformatics (Oxford, England) 21, 2200-2209.
81. Zhang, H., Kong, B., Qu, X., Jia, L., Deng, B., and Yang, Q. (2006) Biomarker discovery for ovarian cancer using SELDI-TOFMS. Gynecol Oncol 102, 61-66.
82. Cowherd, S. M., Espina, V. A., Petricoin, E. F., 3rd, and Liotta, L. A. (2004) Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 5, 385-392.
83. Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., and Petricoin, E. F., 3rd (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84.
84. Chatterjee, M., Ionan, A., Draghici, S., and Tainsky, M. A. (2006) Epitomics: global profiling of immune response to disease using protein microarrays. Omics 10, 499-506.
85. Massion, P. P., and Caprioli, R. M. (2006) Proteomic strategies for the characterization and the early detection of lung cancer. J Thorac Oncol 1, 1027-1039.
86. Vazquez-Martin, A., Colomer, R., and Menendez, J. A. (2007) Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 43, 1117-1124.
87. Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Evans, D. B., Hamer, P., Brown-Shimer, S., Pierce, K., and Carney, W. (2007) Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109, 1933-1939.
88. Haberler, C., Laggner, U., Slavc, I., Czech, T., Ambros, I. M., Ambros, P. F., Budka, H., and Hainfellner, J. A. (2006) Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 30, 1462-1468.
89. Khwaja, F. W., Reed, M. S., Olson, J. J., Schmotzer, B. J., Gillespie, G. Y., Guha, A., Groves, M. D., Kesari, S., Pohl, J., and Meir, E. G. (2007) Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6, 559-570.
90. Hoshino, M., Fukui, H., Ono, Y., Sekikawa, A., Ichikawa, K., Tomita, S., Imai, Y., Imura, J., Hiraishi, H., and Fujimori, T. (2007) Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 74, 15-21.
91. Chua, M. S., Sun, H., Cheung, S. T., Mason, V., Higgins, J., Ross, D. T., Fan, S. T., and So, S. (2007) Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20, 76-83.
92. Ziv, T., Barnea, E., Segal, H., Sharon, R., Beer, I., and Admon, A. (2006) Comparative proteomics of small cell lung carcinoma. Cancer Biomark 2, 219-234.
93. Tsutsumida, H., Nomoto, M., Goto, M., Kitajima, S., Kubota, I., Hirotsu, Y., Wakimoto, J., Hollingsworth, M. A., and Yonezawa, S. (2007) A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 20, 638-647.
94. Chauhan, S. C., Singh, A. P., Ruiz, F., Johansson, S. L., Jain, M., Smith, L. M., Moniaux, N., and Batra, S. K. (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 19, 1386-1394.
95. Buchynska, L. G., Nesina, I. P., Yurchenko, N. P., Bilyk, O. O., Grinkevych, V. N., and Svintitsky, V. S. (2007) Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors. Exp Oncol 29, 49-53.
96. Tassi, R. A., Bignotti, E., Rossi, E., Falchetti, M., Donzelli, C., Calza, S., Ravaggi, A., Bandiera, E., Pecorelli, S., and Santin, A. D. (2007) Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol 105, 578-585.
97. Petri, A. L., Hogdall, E., Christensen, I. J., Kjaer, S. K., Blaakaer, J., and Hogdall, C. K. (2006) Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. Apmis 114, 359-363.
98. Aldovini, D., Demichelis, F., Doglioni, C., Di Vizio, D., Galligioni, E., Brugnara, S., Zeni, B., Griso, C., Pegoraro, C., Zannoni, M., Gariboldi, M., Balladore, E., Mezzanzanica, D., Canevari, S., and Barbareschi, M. (2006) M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 119, 1920-1926.
99. Thompson, I. M., and Ankerst, D. P. (2007) Prostate-specific antigen in the early detection of prostate cancer. Cmaj 176, 1853-1858.
100. Ramp, U., Mahotka, C., Heikaus, S., Shibata, T., Grimm, M. O., Willers, R., and Gabbert, H. E. (2007) Expression of heat shock protein 70 in renal cell carcinoma and its relation to tumor progression and prognosis. Histol Histopathol 22, 1099-1107.
101. Rothhammer, T., Wild, P. J., Meyer, S., Bataille, F., Pauer, A., Klinkhammer-Schalke, M., Hein, R., Hofstaedter, F., and Bosserhoff, A. K. (2007) Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 3, 111-117.
102. Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., and Ueda, S. (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56, 1173-1182.